Table 2.

Clinical outcomes at 10 years in patients with and without diabetes mellitus, hazard ratios, by treatment group

	Patients with diabetes mellitus				Patients without diabetes mellitus
	PF-SES N = 575	HR (95% CI) PF-SES versus DP-ZES	DP-ZES N = 295	P	PF-SES N = 1427	HR (95% CI) PF-SES versus DP-ZES	DP-ZES N = 705	P
MACE	403 (74.8)	0.86 (0.73–1.02)	225 (79.6)	0.08	855 (62.5)	0.99 (0.88–1.11)	420 (62.2)	0.88
All-cause death	228 (44.8)	0.84 (0.68–1.04)	135 (50.1)	0.11	409 (31.2)	0.96 (0.81–1.13)	208 (32.0)	0.60
Any myocardial infarction	42 (8.0)	0.97 (0.58–1.63)	22 (8.3)	0.92	61 (4.7)	1.00 (0.64–1.54)	30 (4.7)	0.99
Any revascularization	266 (53.2)	0.92 (0.75–1.13)	140 (57.4)	0.43	554 (42.6)	1.00 (0.90–1.16)	269 (42.3)	0.97
Cardiac death	163 (36.0)	0.89 (0.69–1.15)	91 (39.3)	0.38	275 (23.2)	1.06 (0.86–1.31)	126 (22.0)	0.60
Target vessel related myocardial infarction	27 (4.9)	0.72 (0.40–1.30)	19 (7.3)	0.27	42 (3.3)	0.94 (0.56–1.57)	22 (3.3)	0.80
TLR	126 (27.1)	0.95 (0.71–1.28)	66 (29.7)	0.75	245 (20.0)	1.10 (0.87–1.37)	109 (17.5)	0.43

Data are shown as number (Kaplan–Meier estimates as percentages), hazard ratios are derived from Cox proportional hazard models, and P values are derived from Cox proportional hazard models. PF-SES indicates biodegradable polymer-free sirolimus- and probucol-eluting stent; DP-ZES indicates durable polymer zotarolimus- eluting stent, MACE = major adverse cardiac events, defined as the composite of all-cause death, any myocardial infarction and any revascularization